1 / 13

Major Crossmatch versus Type&Screen : Why to choose for Type&Screen

Major Crossmatch versus Type&Screen : Why to choose for Type&Screen. Major Vandenvelde Christian, Physician – Biologist, Head of Military Service for Blood Transfusion, Head of Brugmann U.H.C. / Queen Fabiola Children U.H.C. / C.T.R. / Heysel R.C. Immuno - Haematology Laboratory.

afya
Download Presentation

Major Crossmatch versus Type&Screen : Why to choose for Type&Screen

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Major Crossmatch versus Type&Screen : Why to choose for Type&Screen Major Vandenvelde Christian, Physician – Biologist, Head of Military Service for Blood Transfusion, Head of Brugmann U.H.C. / Queen Fabiola Children U.H.C. / C.T.R. / Heysel R.C. Immuno - Haematology Laboratory

  2. What is a Major Crossmatch ? • Compatible RBC Bag(s) request → • Patient RBC ABO-D(-CcEe)(-K) Typing → • Typing-compatible RBC Bag(s) selection → • Bag(s) RBC crossmatching with Patient plasma → • Bag(s) RBC compatible with Patient plasma → RBC Bag(s) reservation for Patient • What if positive Major Crossmatch ?

  3. What is a Type&Screen ? • Compatible RBC Bag(s) request → • Patient RBC ABO-D(-CcEe)(-K) Typing + Patient plasma Screening for Irregular anti-RBC Ab by “crossmatching” with commercially available selected 3-RBC-panel(s) → • Patient plasma negative IAT → Typing-compatible RBC Bag(s) selection when needed • What if positive IAT ?

  4. What if positive MXM / IAT ? • Positive MXM → • Either : further Bag(s) RBC Crossmatching with Patient plasma • Or : Patient plasma Screening for Irregular anti-RBC Ab → … • Positive IAT → • Irregular anti-RBC Ab Identification with commercially available 11-RBC-panel(s) → Typing- & Identification-compatible RBC Bag(s) selection when needed • What if available Bag(s) RBC were not phenotyped for concerned Ag ? • What if Patient anti-RBC Ab remain(s) unidentified ?

  5. What if unidentified Patient Ab / non-phenotyped Bag(s) RBC Ag ? • Available Typing-compatible Bags RBC Crossmatching with Patient plasma • Available Typing-compatible Bags RBC phenotyping for concerned Ag • Typing- / Identification-compatible RBC Bag(s) searching by B.T.C. in : • national BTI RBC Bags stocks • international BTI Frozen-Phenotyped-RBC Bags stocks

  6. PRELIMINARY CONCLUSION • Most of the time the right question will be : “Why to choose either for MXM or for T&S as FIRST RBC compatibility test ?” • 4 Ways to go : • MXM only → Example : Q.A.M.H. Blood Bank • T&S only → Example : Military Ops Support • First T&S, then MXM → Example : Brugmann U.H.C. (Laeken + Schaerbeek + Jette sites) / Queen Fabiola Children U.H.C. / Centre for Traumatology & Rehabilitation / Heysel Rehabilitation Centre Blood Bank • First MXM, then T&S → Example(s) : cfr previous presentation

  7. Type&Screen resources constraints • Reagents : commercially available Screening RBC-panels are expensive but → • Technologists : Screening procedures are easy to automate but → • Equipments : Screening automates are expensive but → • RBC Bags stock : Screening allows • an average RBC Bags stock reduction of +/- 33% • an average RBC Bags expiry rate reduction of +/- 95%, especially when a M.S.B.O.S. has been successfully implemented, but →

  8. Type&Screen Patient risks • Screening misses 1 allo-Ab per 3000 RBC compatibility tests but → • Screening misses 1 weakly-reactive potentially clinically significant allo-Ab per 30000 RBC compatibility tests but → • Screening-missed allo-Ab likely would not result in life-threatening reactions but → • Screening misses clerical ABO-compatibility RBC Bags selection / labelling errors but → • Screening is mandatory followed by an ABO-compatibility check but → • Screening misses allo-Ab present in residual plasma of RBC Bags but → • National BTIs have to warrant the absence of clinically significant allo-Ab in produced L.B.C.

  9. MXM only : Burn Unit Q.A.M.H. Blood Bank support • Reagents & Equipments : • no de novo allo-Ab in 13 years • 3 allo-Ab at admission in 13 years • +/- 66% of requested RBC Bags are transfused • Technologists : • no experience in allo-Ab identification • 1 MXM for 2 RBC Bags from same apheresis donor • presence required for other lab tasks • RBC Bags stock : 2 times the average number of transfused RBC Bags • Patients risks : ABO-D-CcEe-Kk-compatible RBC Bags are electronically selected

  10. T&S only : Military Ops Q.A.M.H. Blood Bank support • Reagents, Technologists & Equipments : • Screening before departure makes field-lab compatibility testing useless • Screening-positive soldiers remain in Belgium (0.01%) • RBC Bags stock : 20 refrigerated + 1200 frozen O Rh/K-negative RBC Bags are continuously available • Patients risks : • O Rh/K-negative RBC Bags are “universal” • RBC Bags are systematically tested for auto- & allo-Ab • Donor Typing occurs at least 2 times before first donation

  11. First T&S, then MXM : Brugmann Blood Bank resources constraints • Reagents : unusually high frequency of allo-immunised, polytransfused & multipregnancy patients • Technologists : • important experience in allo-Ab identification • 4 years ago, 15% of requested RBC Bags were transfused • Equipments : 4 years ago, unusually high frequency of RBC Bags requests • RBC Bags stock : after 4 years, RBC Bags needs & expiry rates have already been reduced by 33% & 85%, respectively

  12. First T&S, then MXM : Brugmann Blood Bank risks management • Extended phenotyping of haematology / oncology patients at first admission • As extended as possible electronic-crossmatch for haematology / oncology / childbearing patients • Maximal use of ABO-D-CcEe-Kk-DAT-IAT screened RBC Bags • Maximal availability of extendedly phenotyped RBC Bags • ABO-compatibility check at patient’s bed

  13. FINAL CONCLUSION • QUESTION : “Why to choose either for Major Crossmatch or for Type & Screen as (FIRST) RBC compatibility test ?” • ANSWER : “It only depends on hospital blood bank human and material resources and patients risks management capabilities”

More Related